https://ir.icecure-medical.com/ https://ir.icecure-medical.com/news-events/press-releases https://ir.icecure-medical.com/news-events/ir-calendar https://ir.icecure-medical.com/news-events/presentations https://ir.icecure-medical.com/news-events/email-alerts https://ir.icecure-medical.com/company-information https://ir.icecure-medical.com/company-information/executive-team https://ir.icecure-medical.com/company-information/contacts https://ir.icecure-medical.com/company-information/faq https://ir.icecure-medical.com/financial-information/financial-results https://ir.icecure-medical.com/financial-information/income-statement https://ir.icecure-medical.com/financial-information/balance-sheet https://ir.icecure-medical.com/financial-information/cash-flow https://ir.icecure-medical.com/stock-data/quote-chart https://ir.icecure-medical.com/stock-data/historical-data https://ir.icecure-medical.com/stock-data/analyst-coverage https://ir.icecure-medical.com/sec-filings/all-sec-filings https://ir.icecure-medical.com/sec-filings/annual-reports https://ir.icecure-medical.com/sec-filings/quarterly-reports https://ir.icecure-medical.com/sec-filings/section-16-filings https://ir.icecure-medical.com/corporate-governance https://ir.icecure-medical.com/corporate-governance/board-of-directors https://ir.icecure-medical.com/corporate-governance/board-committees https://ir.icecure-medical.com/corporate-governance/governance-documents https://ir.icecure-medical.com/corporate-governance/board-diversity https://ir.icecure-medical.com/news-events/press-releases/detail/216/icecure-announces-pricing-of-4-0-million-registered-direct-offering-and-concurrent-private-placement https://ir.icecure-medical.com/news-events/press-releases/detail/215/icecure-reports-positive-5-year-top-line-results-from-icesecret-kidney-cancer-cryoablation-study-89-4-and-83-9-recurrence-free-rates https://ir.icecure-medical.com/news-events/press-releases/detail/214/icecure-appoints-meir-peleg-as-chief-financial-officer https://ir.icecure-medical.com/news-events/press-releases/detail/213/icecure-reports-2025-full-year-financial-operational-results https://ir.icecure-medical.com/news-events/press-releases/detail/212/u-s-fda-approves-icecures-post-marketing-choice-study-for-prosense-cryoablation-in-the-local-treatment-of-low-risk-breast-cancer https://ir.icecure-medical.com/news-events/press-releases/detail/211/icecure-medical-to-report-2025-full-year-financial-and-operating-results-on-march-17-2026 https://ir.icecure-medical.com/news-events/press-releases/detail/210/american-society-of-breast-surgeons-asbrs-resource-guide-update-recommends-cryoablation-for-low-risk-breast-cancer https://ir.icecure-medical.com/news-events/press-releases/detail/209/icecure-medical-reports-independent-study-published-in-plos-one-demonstrating-prosense-cryoablation-safe-and-effective-in-treatment-of-breast-fibroadenomas https://ir.icecure-medical.com/news-events/press-releases/detail/208/icecure-medical-successfully-completes-5-year-patient-follow-up-in-icesecret-kidney-cancer-cryoablation-study-final-analysis-expected-in-second-quarter-of-2026 https://ir.icecure-medical.com/news-events/press-releases/detail/207/icecure-announces-thomas-hospital-of-infirmary-health-installs-prosense-becomes-first-hospital-in-alabama-to-offer-breast-cancer-cryoablation https://ir.icecure-medical.com/news-events/press-releases/detail/206/icecure-announces-shero-imaging-is-first-to-offer-breast-cancer-cryoablation-procedures-in-missouri-with-prosense https://ir.icecure-medical.com/news-events/press-releases/detail/205/icecure-announces-planned-departure-of-cfo-following-nine-years-of-service-and-key-milestones-achieved https://ir.icecure-medical.com/news-events/press-releases/detail/204/icecure-celebrates-american-society-of-breast-surgeons-asbrs-proposed-breast-cancer-treatment-guidelines-which-include-cryoablation-for-low-risk-breast-cancer https://ir.icecure-medical.com/news-events/press-releases/detail/203/icecure-ceo-issues-letter-to-shareholders-reports-record-fourth-quarter-and-full-year-2025-prosense-sales https://ir.icecure-medical.com/news-events/press-releases/detail/202/icecure-expected-to-report-record-fourth-quarter-sales-in-north-america-driven-by-recent-fda-clearance-of-prosense-cryoablation-for-low-risk-breast-cancer https://ir.icecure-medical.com/news-events/press-releases/detail/201/icecures-prosense-cryoablation-featured-in-4-independent-breast-cancer-studies-presented-at-radiological-society-of-america-2025-annual-meeting https://ir.icecure-medical.com/news-events/press-releases/detail/200/icecure-receives-notice-of-patent-allowance-in-china-for-a-novel-cryogen-flow-control-to-optimize-patient-cryoablation-outcomes https://ir.icecure-medical.com/news-events/press-releases/detail/199/icecure-reports-financial-operational-results-for-the-nine-months-ended-september-30-2025 https://ir.icecure-medical.com/news-events/press-releases/detail/198/icecures-prosense-cryoablation-system-receives-regulatory-approval-in-switzerland-for-indications-including-breast-lung-liver-and-kidney-cancer https://ir.icecure-medical.com/news-events/press-releases/detail/197/icecure-medical-announces-receipt-of-nasdaq-minimum-bid-price-notification https://ir.icecure-medical.com/news-events/press-releases/detail/196/icecure-medical-to-report-third-quarter-2025-financial-and-operating-results-on-november-19-2025 https://ir.icecure-medical.com/news-events/press-releases/detail/195/icecure-promotes-shay-levav-to-chief-operating-officer-as-company-ramps-up-for-increased-commercial-traction https://ir.icecure-medical.com/news-events/press-releases/detail/194/icecures-cryoablation-system-combined-with-radiation-therapy-successfully-treats-non-small-cell-lung-cancer-nsclc-with-92-disease-specific-5-year-survival https://ir.icecure-medical.com/news-events/press-releases/detail/193/icecures-prosense-showcased-at-tme-fall-summit-take-the-lead-in-breast-cancer-care-roundtable-highlighting-cryoablation-advances https://ir.icecure-medical.com/news-events/press-releases/detail/192/icecure-medical-to-attend-the-2025-maxim-growth-summit https://ir.icecure-medical.com/news-events/press-releases/detail/191/icecure-medicals-prosense-cryoablation-granted-fda-marketing-authorization-for-treatment-of-low-risk-breast-cancer-in-women-aged-70-and-above-significant-development-in-giving-women-with-breast-cancer-minimally-invasive-care https://ir.icecure-medical.com/news-events/press-releases/detail/190/icecure-receives-fda-marketing-authorization-for-prosense-cryoablation-for-the-treatment-of-low-risk-breast-cancer-in-women-aged-70-and-above https://ir.icecure-medical.com/news-events/press-releases/detail/189/icecures-prosense-at-the-european-society-of-breast-imaging-congress-2025-unlocking-de-escalation-of-care-in-breast-cancer-positive-results-from-5-independent-studies-presented https://ir.icecure-medical.com/news-events/press-releases/detail/188/icecures-prosense-featured-at-cirse-2025-annual-meeting-positive-clinical-results-with-cryoablation-from-4-independent-studies-presented https://ir.icecure-medical.com/news-events/press-releases/detail/187/icecure-granted-notice-of-allowance-for-u-s-patent-for-its-next-generation-xsense-cryoprobes https://ir.icecure-medical.com/news-events/press-releases/detail/186/icecure-receives-regulatory-approval-in-israel-for-its-next-generation-xsense-cryoablation-system-for-breast-cancer-and-other-indications https://ir.icecure-medical.com/news-events/press-releases/detail/185/two-new-publications-from-the-independent-thermac-trial-featuring-icecures-prosense-in-breast-cancer-finds-95-of-patients-satisfied-with-thermal-ablation-prosense-cryoablation-achieves-highest-complete-ablation-rate https://ir.icecure-medical.com/news-events/press-releases/detail/184/icecures-prosense-substantially-reduces-abdominal-wall-endometriosis-pain-with-high-procedural-efficacy https://ir.icecure-medical.com/news-events/press-releases/detail/183/icecure-reports-financial-operational-results-for-the-first-half-of-2025 https://ir.icecure-medical.com/news-events/press-releases/detail/182/icecure-to-report-first-half-2025-financial-and-operating-results-on-august-13-2025 https://ir.icecure-medical.com/news-events/press-releases/detail/181/icecure-announces-expiration-and-results-of-approximately-two-times-over-subscribed-rights-offering-for-aggregate-gross-proceeds-of-10-0-million https://ir.icecure-medical.com/news-events/press-releases/detail/180/icecures-prosense-featured-at-japanese-breast-cancer-society-conference-updated-positive-clinical-data-shows-99-recurrence-free-rate-with-cryoablation https://ir.icecure-medical.com/news-events/press-releases/detail/179/icecure-reminds-shareholders-of-upcoming-expiration-of-rights-offering-subscription-period https://ir.icecure-medical.com/news-events/press-releases/detail/178/icecure-announces-commencement-of-rights-offering https://ir.icecure-medical.com/news-events/press-releases/detail/177/icecure-reports-preliminary-financial-results-for-the-three-and-six-months-ended-june-30-2025 https://ir.icecure-medical.com/news-events/press-releases/detail/176/icecure-announces-record-date-for-rights-offering-for-up-to-10-million https://ir.icecure-medical.com/news-events/press-releases/detail/175/icecure-receives-notice-of-patent-allowance-in-u-s-for-a-novel-cryogen-flow-control-to-optimize-patient-outcomes https://ir.icecure-medical.com/news-events/press-releases/detail/174/icecure-medical-reports-first-quarter-2025-financial-results https://ir.icecure-medical.com/news-events/press-releases/detail/173/icecure-to-report-first-quarter-2025-financial-operational-results-on-may-28-2025 https://ir.icecure-medical.com/news-events/press-releases/detail/172/icecure-receives-high-level-of-interest-from-breast-surgeons-at-asbrs-2025-annual-meeting-following-recent-positive-fda-development-on-prosense-cryoablation https://ir.icecure-medical.com/news-events/press-releases/detail/171/icecure-announces-positive-fda-development-understanding-on-path-forward-for-marketing-authorization-of-prosense-cryoablation-in-women-70-with-early-stage-breast-cancer https://ir.icecure-medical.com/news-events/press-releases/detail/170/icecure-exhibits-prosense-sponsors-breast-cryoablation-courses-at-the-society-of-breast-imaging-symposium https://ir.icecure-medical.com/news-events/press-releases/detail/169/icecures-prosense-featured-at-european-conference-on-interventional-oncology-with-an-emphasis-on-breast-cancer-cryoablation https://ir.icecure-medical.com/news-events/press-releases/detail/168/icecure-medical-reports-2024-financial-results-42-growth-in-prosense-cryoablation-sales-in-north-america https://ir.icecure-medical.com/news-events/press-releases/detail/167/icecures-icesecret-kidney-cancer-cryoablation-study-interim-results-presented-at-european-association-of-urology-conference-in-spain-88-7-recurrence-free-rate https://ir.icecure-medical.com/news-events/press-releases/detail/166/icecure-medical-to-report-2024-full-year-financial-operational-results-on-march-27-2025 https://ir.icecure-medical.com/news-events/press-releases/detail/165/icecure-reports-updated-timeline-and-progress-with-fda-regarding-marketing-authorization-for-prosense-cryoablation-in-early-stage-breast-cancer https://ir.icecure-medical.com/news-events/press-releases/detail/164/icecures-prosense-cryoablation-featured-in-six-studies-presented-at-st-gallen-international-breast-cancer-conference https://ir.icecure-medical.com/news-events/press-releases/detail/163/icecure-receives-notice-of-allowance-in-china-for-novel-cryogenic-pump-for-next-generation-cryoablation-technology https://ir.icecure-medical.com/news-events/press-releases/detail/162/breast-cancer-patients-who-underwent-icecures-prosense-cryoablation-in-japan-reported-significantly-higher-satisfaction-than-patients-who-underwent-standard-of-care-surgery https://ir.icecure-medical.com/news-events/press-releases/detail/161/icecure-submits-filing-for-regulatory-approval-of-its-next-generation-xsense-cryoablation-system-in-israel https://ir.icecure-medical.com/news-events/press-releases/detail/160/icecures-prosense-in-the-spotlight-at-society-of-interventional-oncology-sio-annual-meeting-award-winning-abstract-and-hands-on-training-for-breast-cryoablation-as-medical-community-anticipates-fdas-market-authorization-decision https://ir.icecure-medical.com/news-events/press-releases/detail/159/icecure-files-for-regulatory-approval-of-prosense-cryoablation-system-in-china https://ir.icecure-medical.com/news-events/press-releases/detail/158/icecure-medical-ceo-issues-letter-to-shareholders-reports-increase-of-42-in-prosense-sales-for-2024-in-north-america https://ir.icecure-medical.com/news-events/press-releases/detail/157/icecure-medical-regains-full-nasdaq-compliance-with-nasdaq-minimum-closing-bid-price-rule https://ir.icecure-medical.com/news-events/press-releases/detail/156/european-patent-office-issues-intention-to-grant-notice-to-icecure-for-its-next-generation-cryoablation-technology https://ir.icecure-medical.com/news-events/press-releases/detail/155/data-on-icecures-prosense-cryoablation-for-low-risk-breast-cancer-presented-at-radiological-society-of-north-americas-2024-annual-meeting https://ir.icecure-medical.com/news-events/press-releases/detail/154/icecures-prosense-cryoablation-safe-and-effective-in-destruction-of-kidney-tumors-with-88-7-recurrence-free-rate-based-on-interim-icesecret-study-results https://ir.icecure-medical.com/news-events/press-releases/detail/153/icecure-medical-reports-36-sales-growth-in-the-first-nine-months-of-2024-driven-by-global-adoption-of-prosense-cryoablation https://ir.icecure-medical.com/news-events/press-releases/detail/152/icecures-next-generation-multiprobe-cryoablation-technology-issued-notice-of-allowance-from-japans-patent-office https://ir.icecure-medical.com/news-events/press-releases/detail/151/icecure-medical-to-report-third-quarter-2024-financial-operational-results-on-november-26-2024 https://ir.icecure-medical.com/news-events/press-releases/detail/150/icecures-prosense-chosen-for-breast-cryoablation-study-led-by-the-prestigious-european-institute-of-oncology-with-sponsorship-from-the-italian-ministry-of-health https://ir.icecure-medical.com/news-events/press-releases/detail/149/fda-advisory-panel-votes-in-favor-of-icecures-prosense-cryoablation-benefit-risk-profile-in-early-stage-low-risk-breast-cancer https://ir.icecure-medical.com/news-events/press-releases/detail/148/upcoming-fda-advisory-panel-for-icecures-prosense-marketing-authorization-receives-large-number-of-public-comments-from-stakeholders https://ir.icecure-medical.com/news-events/press-releases/detail/147/icecure-receives-notice-of-allowance-from-u-s-patent-and-trademark-office-for-its-next-generation-cryoablation-system https://ir.icecure-medical.com/news-events/press-releases/detail/146/icecures-prosense-featured-in-6-global-studies-on-cryoablation-of-breast-tumors-at-the-2024-european-society-of-breast-imaging-conference https://ir.icecure-medical.com/news-events/press-releases/detail/145/icecures-ice3-5-year-trial-results-published-in-the-peer-reviewed-annals-of-surgical-oncology-journal-prosense-cryoablation-without-excision-for-early-stage-low-risk-breast-cancer-demonstrates-96-3-recurrence-free-rate https://ir.icecure-medical.com/news-events/press-releases/detail/144/study-published-in-the-british-journal-of-radiology-demonstrates-icecures-prosense-is-a-safe-procedure-with-97-7-technical-success-rate-in-treating-tumors-of-the-lung-bone-and-soft-tissues https://ir.icecure-medical.com/news-events/press-releases/detail/143/icecure-announces-fda-advisory-panel-meeting-date-for-marketing-authorization-of-prosense-in-early-stage-low-risk-breast-cancer-scheduled-for-november-7-2024 https://ir.icecure-medical.com/news-events/press-releases/detail/142/icecure-to-meet-institutional-investors-at-the-h-c-wainwright-and-lake-street-capital-markets-conferences https://ir.icecure-medical.com/news-events/press-releases/detail/141/uspto-grants-notice-of-allowance-for-additional-patent-on-icecures-novel-cryogenic-pump-technology-reinforces-icecures-global-ip-leadership-in-cryoablation-technologies https://ir.icecure-medical.com/news-events/press-releases/detail/140/icecure-medical-reports-20-growth-in-prosense-system-and-probe-sales-for-the-first-half-of-2024-reflects-continued-adoption-in-the-u-s-and-other-global-markets https://ir.icecure-medical.com/news-events/press-releases/detail/139/icecures-prosense-destroyed-100-of-breast-cancer-tumors-in-independent-study-of-patients-who-chose-cryoablation-instead-of-surgery https://ir.icecure-medical.com/news-events/press-releases/detail/138/icecure-medical-to-report-second-quarter-2024-financial-operational-results-on-august-20-2024 https://ir.icecure-medical.com/news-events/press-releases/detail/137/icecure-announces-positive-data-from-the-largest-multi-institutional-study-of-its-kind-cryoablation-of-primary-breast-cancer-in-patients-ineligible-for-clinical-trials https://ir.icecure-medical.com/news-events/press-releases/detail/136/99-74-recurrence-free-rate-for-women-with-breast-cancer-treated-with-icecures-prosense-cryoablation-system-key-findings-delivered-at-32nd-annual-meeting-of-the-japanese-breast-cancer-society https://ir.icecure-medical.com/news-events/press-releases/detail/135/icecure-medical-announces-receipt-of-nasdaq-minimum-bid-price-notification https://ir.icecure-medical.com/news-events/press-releases/detail/134/european-study-provides-more-evidence-supporting-icecures-prosense-is-safe-effective-cryoablation-treatment-for-metastatic-and-recurrent-breast-cancer https://ir.icecure-medical.com/news-events/press-releases/detail/133/u-s-food-and-drug-administration-grants-regulatory-clearance-to-icecure-for-next-gen-xsense-cryoablation-system-with-cryoprobes https://ir.icecure-medical.com/news-events/press-releases/detail/132/icecure-medical-to-provide-overview-and-share-recent-progress-at-northland-capital-markets-virtual-growth-conference-on-june-25-2024 https://ir.icecure-medical.com/news-events/press-releases/detail/131/positive-data-from-icecures-kidney-cancer-clinical-study-presented-at-interventional-radiology-conference-minimally-invasive-approach-results-in-shorter-hospitalization-and-minor-impact-on-renal-function https://ir.icecure-medical.com/news-events/press-releases/detail/130/fda-to-convene-advisory-panel-for-review-of-icecures-de-novo-marketing-clearance-request-for-prosense-decision-expected-early-2025-aligns-with-commercial-readiness-plan https://ir.icecure-medical.com/news-events/press-releases/detail/129/icecure-medical-maintains-positive-momentum-and-reports-sales-growth-for-cryoablation-system-in-first-quarter-of-2024 https://ir.icecure-medical.com/news-events/press-releases/detail/128/icecure-medical-to-report-first-quarter-2024-financial-operational-results-on-may-28-2024 https://ir.icecure-medical.com/news-events/press-releases/detail/127/icecure-medical-to-highlight-key-achievements-and-provide-business-overview-at-a-g-p-alliance-global-partners-virtual-healthcare-company-showcase https://ir.icecure-medical.com/news-events/press-releases/detail/126/independent-study-results-in-japan-demonstrate-zero-0-breast-cancer-local-recurrence-5-years-following-treatment-with-icecures-prosense-adding-to-continued-positive-data-published-globally https://ir.icecure-medical.com/news-events/press-releases/detail/125/icecure-medical-reports-final-ice3-breast-cancer-cryoablation-trial-results-of-100-patient-and-physician-satisfaction-and-96-3-recurrence-free-rate-data-submitted-to-fda-requesting-marketing-authorization-to-treat-early-stage-breast-cancer https://ir.icecure-medical.com/news-events/press-releases/detail/124/icecure-medical-reports-full-year-2023-financial-results-global-prosense-and-disposables-sales-increase-26-as-company-continues-transition-to-commercial-phase-and-expects-to-submit-ice3-breast-cancer-study-data-to-fda-this-month-for-marketing-clearance https://ir.icecure-medical.com/news-events/press-releases/detail/123/icecure-submits-fda-regulatory-filing-for-new-xsense-cryoablation-system-with-cryoprobes https://ir.icecure-medical.com/news-events/press-releases/detail/122/icecure-medical-to-report-2023-full-year-financial-operational-results-on-april-3-2024 https://ir.icecure-medical.com/news-events/press-releases/detail/121/icecure-medical-reports-positive-topline-results-from-ice3-cryoablation-breast-cancer-study-achievement-of-96-39-recurrence-free-rate-brings-company-one-step-closer-to-providing-women-a-non-surgical-alternative-to-lumpectomy https://ir.icecure-medical.com/news-events/press-releases/detail/120/icecure-receives-notice-of-patent-allowance-in-japan-for-a-novel-cryogen-flow-control-to-optimize-patient-outcomes https://ir.icecure-medical.com/news-events/press-releases/detail/119/icecure-medical-to-present-at-34th-annual-oppenheimer-healthcare-medtech-services-conference https://ir.icecure-medical.com/news-events/press-releases/detail/118/icecures-prosense-a-promising-alternative-treatment-for-extra-pelvis-endometriosis-independent-study-presented-at-ecr-2024 https://ir.icecure-medical.com/news-events/press-releases/detail/117/fourth-briit-conference-in-india-features-icecures-prosense-in-breast-cancer-imaging-interventions-workshop https://ir.icecure-medical.com/news-events/press-releases/detail/116/study-using-icecures-prosense-treatment-results-in-100-tumor-reduction-in-early-stage-breast-cancer https://ir.icecure-medical.com/news-events/press-releases/detail/115/icecures-prosense-to-be-featured-at-two-upcoming-medical-conferences-in-japan https://ir.icecure-medical.com/news-events/press-releases/detail/114/u-s-fda-grants-icecure-medicals-appeal-reopens-de-novo-classification-request-for-marketing-authorization-of-prosense-for-early-stage-breast-cancer https://ir.icecure-medical.com/news-events/press-releases/detail/113/icecure-medicals-breast-cryoablation-gains-prominence-in-the-u-s-as-society-of-interventional-oncology-annual-meeting-features-its-first-breast-cryoablation-master-class https://ir.icecure-medical.com/news-events/press-releases/detail/112/icecure-medicals-prosense-featured-at-indian-society-of-vascular-and-interventional-radiology-conference-key-opinion-leaders-highlight-benefits-of-cryoablation https://ir.icecure-medical.com/news-events/press-releases/detail/111/icecure-medical-regains-compliance-with-nasdaq-minimum-closing-bid-price-rule https://ir.icecure-medical.com/news-events/press-releases/detail/110/icecure-medical-ceo-issues-letter-to-shareholders-reports-increase-in-sales-in-preliminary-unaudited-2023-results https://ir.icecure-medical.com/news-events/press-releases/detail/109/new-study-reports-icecures-prosense-boosts-immune-response-against-cancer-enhances-cd8-t-cell-response https://ir.icecure-medical.com/news-events/press-releases/detail/108/study-using-icecures-prosense-finds-cryoablation-allows-the-ultimate-de-escalation-of-surgical-therapy-for-select-breast-cancer-patients https://ir.icecure-medical.com/news-events/press-releases/detail/107/icecures-prosense-deepens-regulatory-approval-in-india https://ir.icecure-medical.com/news-events/press-releases/detail/106/icecure-system-successfully-treated-kidney-cancer-tumor-with-92-disease-free-survival-rate-and-100-secondary-local-control-rate https://ir.icecure-medical.com/news-events/press-releases/detail/105/icecure-medical-reports-financial-results-as-of-and-for-the-nine-months-ended-september-30-2023-and-provides-update-on-recent-operational-highlights https://ir.icecure-medical.com/news-events/press-releases/detail/104/icecure-medical-files-appeal-with-u-s-fda-requesting-a-review-of-its-de-novo-classification-for-prosense-in-early-stage-breast-cancer https://ir.icecure-medical.com/news-events/press-releases/detail/103/icecure-medical-to-report-third-quarter-2023-financial-operational-results-on-november-15-2023 https://ir.icecure-medical.com/news-events/press-releases/detail/102/substantial-evidence-based-data-currently-being-generated-by-19-ongoing-studies-using-icecure-medicals-prosense-cryoablation-system https://ir.icecure-medical.com/news-events/press-releases/detail/101/icecure-medical-announces-receipt-of-nasdaq-minimum-bid-price-notification https://ir.icecure-medical.com/news-events/press-releases/detail/100/icecures-ice3-trial-results-demonstrating-96-91-recurrence-free-rate-featured-in-a-presentation-at-bisicon-2023-in-india https://ir.icecure-medical.com/news-events/press-releases/detail/99/independent-scientific-paper-by-doctors-using-icecures-prosense-published-in-journal-of-breast-imaging-presents-advantages-of-cryoablation-breast-conserving-over-surgery-in-early-breast-cancer-patients https://ir.icecure-medical.com/news-events/press-releases/detail/98/women-deemed-inoperable-for-breast-cancer-benefitted-from-icecure-medicals-prosense-as-an-independent-study-performed-in-italy-showed-a-tumor-reduction-rate-of-93-43-to-96-81 https://ir.icecure-medical.com/news-events/press-releases/detail/97/independent-study-validates-icecures-prosense-cryoablation-is-safe-effective-outpatient-procedure-for-breast-cancer-with-96-8-success-rate https://ir.icecure-medical.com/news-events/press-releases/detail/96/renowned-spanish-radiologist-luca-graa-lpez-to-present-data-using-icecure-medicals-prosense-at-european-society-of-breast-imaging-scientific-meeting-2023 https://ir.icecure-medical.com/news-events/press-releases/detail/95/icecure-medical-receives-fda-response-to-de-novo-classification-request-for-breast-cancer https://ir.icecure-medical.com/news-events/press-releases/detail/94/icecure-medical-to-join-hands-on-cryoablation-session-with-prosense-and-host-symposium-led-by-renowned-doctors-at-the-circe-2023-annual-congress https://ir.icecure-medical.com/news-events/press-releases/detail/93/icecure-medicals-prosense-cryoablation-system-receives-regulatory-approval-in-brazil https://ir.icecure-medical.com/news-events/press-releases/detail/92/icecure-medical-takes-next-major-initiative-as-it-prepares-to-accelerate-the-commercialization-of-prosense-in-u-s-and-canada-appoints-vp-of-sales-north-america https://ir.icecure-medical.com/news-events/press-releases/detail/91/icecure-medical-continues-to-experience-growing-global-interest-in-prosense-featured-at-the-16th-thai-breast-symposium https://ir.icecure-medical.com/news-events/press-releases/detail/90/icecure-medical-reports-first-half-2023-financial-operational-results-global-adoption-of-cryoablation-technology-gaining-momentum https://ir.icecure-medical.com/news-events/press-releases/detail/89/icecure-medical-to-report-second-quarter-2023-financial-operational-results-on-august-14-2023 https://ir.icecure-medical.com/news-events/press-releases/detail/88/health-canada-approves-icecure-medicals-minimally-invasive-prosense-cryoablation-system https://ir.icecure-medical.com/news-events/press-releases/detail/87/icecure-medical-expands-distribution-of-prosense-into-portugal-through-agreement-with-medicinlia-cormdica-upfront-systems-probes-sales https://ir.icecure-medical.com/news-events/press-releases/detail/86/icecure-medical-to-review-recent-progress-at-maxim-groups-virtual-healthcare-conference https://ir.icecure-medical.com/news-events/press-releases/detail/85/icecures-prosense-installation-in-india-is-the-first-to-offer-cryoablation-for-the-treatment-of-breast-cancer-in-the-country https://ir.icecure-medical.com/news-events/press-releases/detail/84/icecure-medical-reports-first-quarter-2023-financial-operational-results https://ir.icecure-medical.com/news-events/press-releases/detail/83/icecure-to-report-first-quarter-2023-financial-operational-results-on-may-22-2023 https://ir.icecure-medical.com/news-events/press-releases/detail/82/icecure-to-report-first-quarter-2023-financial-operational-results-on https://ir.icecure-medical.com/news-events/press-releases/detail/81/cryoablation-takes-center-stage-at-american-society-of-breast-surgeons-24th-annual-meeting https://ir.icecure-medical.com/news-events/press-releases/detail/80/icecure-medical-to-provide-educational-support-in-a-first-of-its-kind-cryotherapy-course-at-the-american-society-of-breast-surgeons-24th-annual-meeting https://ir.icecure-medical.com/news-events/press-releases/detail/79/icecures-prosense-system-used-in-endometriosis-cryoablation-study-that-demonstrated-efficacy-rate-of-92-8-to-avoid-secondary-surgery https://ir.icecure-medical.com/news-events/press-releases/detail/78/icecure-medical-ordinary-shares-to-trade-exclusively-on-nasdaq-company-to-voluntarily-delist-shares-from-trading-on-the-tel-aviv-stock-exchange https://ir.icecure-medical.com/news-events/press-releases/detail/77/icecure-medical-reports-2022-full-year-financial-results-recent-corporate-developments-milestone-achievements-expected-to-drive-revenue-growth-in-2023 https://ir.icecure-medical.com/news-events/press-releases/detail/76/icecure-medical-receives-regulatory-approval-in-china-for-commercial-use-of-its-icesense3-disposable-cryoprobes https://ir.icecure-medical.com/news-events/press-releases/detail/75/icecure-medical-to-report-2022-full-year-financial-operational-results-on-march-29-2023 https://ir.icecure-medical.com/news-events/press-releases/detail/74/icecure-medical-announces-preliminary-unaudited-2022-year-end-financial-results-recent-operational-highlights https://ir.icecure-medical.com/news-events/press-releases/detail/73/icecures-prosense-featured-in-breast-session-at-the-society-of-interventional-oncologys-annual-scientific-meeting-in-washington-d-c https://ir.icecure-medical.com/news-events/press-releases/detail/72/icecures-prosense-presented-in-hands-on-training-course-at-the-american-society-of-breast-surgeons-breast-follows-ultrasound-course https://ir.icecure-medical.com/news-events/press-releases/detail/71/u-s-patent-office-grants-notice-of-allowance-to-icecure-for-novel-cryogenic-pump-for-next-generation-cryoablation-systems https://ir.icecure-medical.com/news-events/press-releases/detail/70/icecure-receives-notice-of-patent-allowance-in-japan-for-a-novel-cryogenic-pump-for-its-next-generation-cryoablation-systems https://ir.icecure-medical.com/news-events/press-releases/detail/69/icecure-medical-ceo-issues-letter-to-shareholders https://ir.icecure-medical.com/news-events/press-releases/detail/68/icecure-medical-ltd-announces-closing-of-14-5-million-public-offering-priced-at-the-market-under-nasdaq-rules https://ir.icecure-medical.com/news-events/press-releases/detail/67/icecure-medical-ltd-announces-pricing-of-14-5-million-public-offering-priced-at-the-market-under-nasdaq-rules https://ir.icecure-medical.com/news-events/press-releases/detail/66/icecure-medical-ltd-announces-proposed-public-offering https://ir.icecure-medical.com/news-events/press-releases/detail/65/icecures-prosense-safe-and-effective-in-treating-kidney-tumors-with-89-5-recurrence-free-rate-based-on-interim-study-results https://ir.icecure-medical.com/news-events/press-releases/detail/64/icecure-appoints-vincent-chun-hung-chan-to-serve-as-an-independent-director-on-its-board-of-directors https://ir.icecure-medical.com/news-events/press-releases/detail/63/icecure-medical-reports-financial-results-for-the-nine-months-ended-september-30-2022-and-provides-update-on-recent-operational-highlights https://ir.icecure-medical.com/news-events/press-releases/detail/62/icecures-prosense-featured-in-poster-presentation-at-radiological-society-of-north-americas-2022-annual-meeting https://ir.icecure-medical.com/news-events/press-releases/detail/61/time-change-icecure-medical-to-report-financial-results-for-the-9-month-period-ended-september-30-2022-and-conduct-conference-call-on-december-5-2022 https://ir.icecure-medical.com/news-events/press-releases/detail/60/icecure-medical-to-report-financial-results-for-the-9-month-period-ended-september-30-2022-and-conduct-conference-call-on-december-5-2022 https://ir.icecure-medical.com/news-events/press-releases/detail/59/icecures-prosense-achieves-significant-milestone-in-medicare-coverage-of-breast-cancer-procedures https://ir.icecure-medical.com/news-events/press-releases/detail/58/icecure-launches-global-freezecancernotyourlife-movement-during-breast-cancer-awareness-month https://ir.icecure-medical.com/news-events/press-releases/detail/57/icecure-files-de-novo-classification-request-with-the-fda-for-marketing-authorization-of-prosense-with-breakthrough-indication-early-stage-low-risk-breast-cancer-patients-at-high-risk-to-surgery https://ir.icecure-medical.com/news-events/press-releases/detail/56/icecure-medicals-prosense-cryoprobes-and-introducers-receive-regulatory-approval-in-brazil https://ir.icecure-medical.com/news-events/press-releases/detail/55/icecure-submits-regulatory-filing-in-vietnam-for-approval-of-prosense https://ir.icecure-medical.com/news-events/press-releases/detail/54/icecure-medical-reports-financial-results-for-the-first-half-of-2022-and-recent-operational-highlights https://ir.icecure-medical.com/news-events/press-releases/detail/53/icecure-medical-to-report-h1-2022-results-and-conduct-conference-call-on-august-15-2022 https://ir.icecure-medical.com/news-events/press-releases/detail/52/icecure-announces-regulatory-filing-submission-for-approval-of-prosense-in-canada-for-indications-including-ablation-of-benign-and-malignant-breast-tumors https://ir.icecure-medical.com/news-events/press-releases/detail/51/former-itamar-medical-ceo-president-gilad-glick-joins-icecure-medical-as-a-strategic-advisor-for-global-go-to-market-operations https://ir.icecure-medical.com/news-events/press-releases/detail/50/tracking-news---more-details-of-marketing-progress-for-icesense3-in-mainland-china https://ir.icecure-medical.com/news-events/press-releases/detail/49/icecures-prosense-featured-at-sir-2022-annual-meeting-in-breast-cancer-cryoablation-categorical-course https://ir.icecure-medical.com/news-events/press-releases/detail/48/icecure-medical-shanghai-medtronic-turing-medical-sign-distribution-agreement-in-mainland-china https://ir.icecure-medical.com/news-events/press-releases/detail/47/icecure-medicals-prosense-cryoablation-system-submitted-for-regulatory-approval-in-brazil https://ir.icecure-medical.com/news-events/press-releases/detail/46/icecure-medical-reports-first-quarter-2022-financial-results-and-operational-highlights https://ir.icecure-medical.com/news-events/press-releases/detail/45/icecure-medical-to-report-q1-2022-results-and-conduct-conference-call-may-18-2022 https://ir.icecure-medical.com/news-events/press-releases/detail/44/icecure-medical-presents-ice3-breast-cancer-trial-interim-data-hosts-cryoablation-symposium-conducts-hands-on-prosense-training-sessions-at-the-european-conference-on-interventional-oncology https://ir.icecure-medical.com/news-events/press-releases/detail/43/icecure-medical-announces-preliminary-unaudited-2021-year-end-financial-results https://ir.icecure-medical.com/news-events/press-releases/detail/42/icecure-medical-ceo-issues-letter-to-shareholders https://ir.icecure-medical.com/news-events/press-releases/detail/41/icecure-medical-receives-notice-of-intention-to-grant-a-european-patent-covering-its-cryogenic-pump https://ir.icecure-medical.com/news-events/press-releases/detail/40/icecure-medical-ltd-closes-17-million-underwritten-public-offering-and-partial-exercise-of-over-allotment-option https://ir.icecure-medical.com/news-events/press-releases/detail/39/icecure-medical-ltd-announces-pricing-of-15-million-underwritten-public-offering https://ir.icecure-medical.com/news-events/press-releases/detail/38/icecure-medicals-interim-results-of-the-ice3-clinical-trial-for-early-stage-breast-cancer-cryoablation-featured-at-the-2021-annual-meeting-of-the-radiological-society-of-north-america https://ir.icecure-medical.com/news-events/press-releases/detail/37/icecure-medical-announces-appointment-of-merav-nir-dotan-to-vice-president-human-resources https://ir.icecure-medical.com/news-events/press-releases/detail/36/icecure-medical-reports-financial-results-as-of-and-for-the-first-nine-months-of-2021-and-recent-corporate-developments https://ir.icecure-medical.com/news-events/press-releases/detail/35/icecure-medical-announces-new-independent-data-published-in-the-journal-of-cancer-therapy-showing-that-percutaneous-cryoablation-presents-a-potential-substitute-for-lumpectomy-for-tumors-15mm-using-prosense https://ir.icecure-medical.com/news-events/press-releases/detail/34/icecure-medical-enters-into-an-exclusive-agreement-in-poland-for-distribution-of-the-prosense-cryoablation-system https://ir.icecure-medical.com/news-events/press-releases/detail/5/icecure-medical-announces-updated-regulatory-strategy-in-china-for-the-icesense3-system-to-treat-cancerous-tumors-with-cryoablation https://ir.icecure-medical.com/news-events/press-releases/detail/6/icecure-medical-reports-financial-results-for-the-first-half-of-2021-and-recent-operating-highlights https://ir.icecure-medical.com/news-events/press-releases/detail/7/icecure-medical-announces-first-peer-reviewed-publication-for-the-3-year-interim-analysis-of-the-ice3-trial-on-cryoablation-of-low-risk-early-stage-breast-cancer https://ir.icecure-medical.com/news-events/press-releases/detail/8/icecure-medical-announces-exclusive-distribution-agreement-to-sell-prosense-cryoablation-system-in-turkey https://ir.icecure-medical.com/news-events/press-releases/detail/9/icecure-medical-shares-to-begin-trading-on-nasdaq-capital-market-on-august-26-2021 https://ir.icecure-medical.com/news-events/press-releases/detail/10/c-o-r-r-e-c-t-i-o-n----icecure-medical https://ir.icecure-medical.com/news-events/press-releases/detail/11/icecure-medical-announces-exclusive-6-6m-distribution-agreement-to-sell-prosense-cryoablation-system-in-brazil https://ir.icecure-medical.com/news-events/press-releases/detail/12/positive-interim-results-from-icecure-medicals-ice3-clinical-trial-for-breast-cancer-treatment-by-freezing-with-the-prosense-cryoablation-system-presented-at-the-2021-asbrs-meeting https://ir.icecure-medical.com/news-events/press-releases/detail/13/icecure-medical-announces-upcoming-presentation-at-the-american-society-of-breast-surgeons-annual-meeting https://ir.icecure-medical.com/news-events/press-releases/detail/14/icecure-medical-granted-fda-breakthrough-device-designation-for-prosense-cryoablation-system https://ir.icecure-medical.com/news-events/press-releases/detail/15/icecure-to-present-at-the-h-c-wainwright-global-life-sciences-conference https://ir.icecure-medical.com/news-events/press-releases/detail/16/icecure-signs-exclusive-distribution-agreement-with-rise-general-trading-lcc-expanding-market-reach-across-the-middle-east https://ir.icecure-medical.com/news-events/press-releases/detail/17/icecure-inks-expanded-distribution-agreement-with-terumo-corporation-for-thailand https://ir.icecure-medical.com/news-events/press-releases/detail/18/icecure-expands-strategic-collaboration-with-terumo-new-commercial-distribution-agreement-potentially-valued-at-over-7-0-million https://ir.icecure-medical.com/news-events/press-releases/detail/19/icecure-raises-nis-20-7-million-in-equity-share-offering-received-oversubscribed-demand-of-nis-24-million https://ir.icecure-medical.com/news-events/press-releases/detail/20/icecures-global-expansion-accelerates-tumor-freezing-product-now-approved-for-market-in-india https://ir.icecure-medical.com/news-events/press-releases/detail/21/icecure-enters-german-cryoablation-oncology-market-inks-exclusive-distribution-agreement-with-mts-medical-technology https://ir.icecure-medical.com/news-events/press-releases/detail/22/icecure-continues-global-expansion-to-freeze-tumors https://ir.icecure-medical.com/news-events/press-releases/detail/23/icecure-medical-continues-expansion-in-asia-receives-largest-purchase-order-for-prosense-cryoablation-system https://ir.icecure-medical.com/news-events/press-releases/detail/24/icecure-receives-fda-clearance-for-expanded-indications-of-cryoablation-technology-and-regulatory-approval-of-new-multisense-system-plans-to-increase-u-s-presence-and-operations https://ir.icecure-medical.com/news-events/press-releases/detail/25/icecure-medical-appoints-medical-device-veteran-sharon-levita-to-its-board-of-directors https://ir.icecure-medical.com/news-events/press-releases/detail/26/another-success-icecure-receives-israeli-amar-approval-for-use-of-its-freezing-technology-in-specific-indications-following-an-earlier-general-approval https://ir.icecure-medical.com/news-events/press-releases/detail/27/icecure-medical-announces-new-category-iii-cpt-code-for-breast-cryoablation-therapy-issued-by-the-american-medical-association https://ir.icecure-medical.com/news-events/press-releases/detail/28/icecure-medical-presents-promising-results-from-first-ever-interventional-radiology-study-with-its-next-generation-liquid-nitrogen-ln2-cryoablation-system-prosense https://ir.icecure-medical.com/news-events/press-releases/detail/29/recent-american-society-of-breast-surgeons-asbrs-guidelines-are-favorable-to-next-generation-cryoablation-developer-icecure-medical https://ir.icecure-medical.com/news-events/press-releases/detail/30/icecure-medical-inc-announces-commencement-of-ice3-clinical-trial-for-breast-cancer https://ir.icecure-medical.com/news-events/press-releases/detail/31/icecure-medical-ltd-announces-treatment-of-first-breast-cancer-patient-using-its-icesense3-cryoablation-system-at-john-wayne-cancer-institute https://ir.icecure-medical.com/news-events/press-releases/detail/32/use-of-cryoablation-for-treatment-of-breast-cancer-shows-promising-results https://ir.icecure-medical.com/news-events/press-releases/detail/33/first-breast-cancer-patients-treated-with-minimally-invasive-icesense3-cryoablation-procedure https://ir.icecure-medical.com/disclaimer https://ir.icecure-medical.com/sitemap